{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:55:30Z","timestamp":1786737330672,"version":"build-2736575974"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Ophthalmol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijo.ijo_1644_20","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T13:06:33Z","timestamp":1597928793000},"page":"1986","source":"Crossref","is-referenced-by-count":9,"title":["Worsening of posterior scleritis and orbital pseudotumor in a patient with granulomatosis polyangiitis with rituximab-A case report"],"prefix":"10.4103","volume":"68","author":[{"given":"Kalpana","family":"Babu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BG","family":"Dharmanand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0301-4738.292538-1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1080\/09273948.2017.1327602","article-title":"Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener's)","author":"You","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"key-10.4103\/0301-4738.292538-2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ophtha.2015.01.016","article-title":"Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease","author":"Joshi","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.292538-3","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: Results of a phase I\/II dose-ranging, randomized, clinical trial","author":"Suhler","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.292538-4","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jamaophthalmol.2013.8179","article-title":"Rituximab therapy for refractory orbital inflammation: Results of a phase 1\/2, dose-ranging, randomized clinical trial","author":"Suhler","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"key-10.4103\/0301-4738.292538-5","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.jcjo.2018.12.004","article-title":"Ocular and orbital exacerbation after rituximab therapy for granulomatosis with polyangiitis","author":"Shih","year":"2019","journal-title":"Can J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:53:03Z","timestamp":1786733583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1644_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"alternative-id":["292538"],"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1644_20","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}